Ji Ruijun, Yu Kai, Li Guoyang, Liu Xinyu, Yan Yinglin, Gao Suying, Yang Hongna, Qin Shangmin, Li Fang, Zhang Guangbo, Yang Bo, He Yan, Zhao Yongna, Li Enjing, Xu Lihua, Zhang Na, Fan Dongna, Liu Dongliang
a Department of Neurology, Tiantan Hospital , Capital Medical University , Beijing , China.
b Department of rehabilitation medicine (Neurorehabilitation), Tiantan Hospital , Capital Medical University , Beijing , China.
Neurol Res. 2019 May;41(5):456-465. doi: 10.1080/01616412.2019.1576375. Epub 2019 Feb 13.
To develop and validate a risk model (Extracranial Carotid Artery Stenosis progression score, ECAS-PS) and to predict risk of ECAS progression.
The ECAS-PS was developed based on the Renqiu Stroke Screening Study (RSSS), in which eligible participants were randomly divided into derivation (60%) and validation (40%) cohorts. ECAS at baseline and follow-up was diagosed by carotid duplex ultrasound according to the published criteria. ECAS progression was defined as an increase in ECAS to≥50% for those with a baseline of <50% or as an increase to a higher category of stenosis if the baseline stenosis was ≥50%. Independent predictors of ECAS progression were obtained using multivariable logistic regression. The area under the receiver operating characteristic curve (AUROC) and the Hosmer-Lemeshow test were used to assess model discrimination and calibration.
A total of 4111 participants were included and the mean age was 64.3. A total number of 29 (0.7%), 24 (0.6%) and 48 (1.2%) patients progressed during 2-year follow-up for left, right and bilateral (either left or right) carotid artery, respectively. The ECAS-PS was developed from a set of predictors of ECAS progression. The ECAS-PS demonstrated good discrimination in both the derivation and validation cohorts (AUROC range: 0.824-0.917). The Hosmer-Lemeshow tests of ECAS progression score were not significant in the derivation and validation cohorts (all P > 0.05).
The ECAS progression score is a valid model for predicting the risk of ECAS progression. Further validation of the ECAS-PS in different populations and larger samples is warranted.
开发并验证一种风险模型(颅外颈动脉狭窄进展评分,ECAS - PS),并预测颅外颈动脉狭窄(ECAS)进展的风险。
ECAS - PS基于任丘卒中筛查研究(RSSS)开发,符合条件的参与者被随机分为推导队列(60%)和验证队列(40%)。根据已发表的标准,通过颈动脉双功超声诊断基线和随访时的ECAS。ECAS进展定义为:基线狭窄<50%者,ECAS增加至≥50%;或基线狭窄≥50%者,狭窄程度增加到更高类别。使用多变量逻辑回归获得ECAS进展的独立预测因素。采用受试者工作特征曲线下面积(AUROC)和Hosmer - Lemeshow检验评估模型的辨别力和校准度。
共纳入4111名参与者,平均年龄为64.3岁。在2年随访期间,分别有29例(0.7%)、24例(0.6%)和48例(1.2%)患者左侧、右侧和双侧(左侧或右侧)颈动脉出现进展。ECAS - PS由一组ECAS进展的预测因素推导得出。ECAS - PS在推导队列和验证队列中均表现出良好的辨别力(AUROC范围:0.824 - 0.917)。ECAS进展评分的Hosmer - Lemeshow检验在推导队列和验证队列中均无统计学意义(所有P>0.05)。
ECAS进展评分是预测ECAS进展风险的有效模型。有必要在不同人群和更大样本中对ECAS - PS进行进一步验证。